Clinical immunoadjuvant studies with tilorone, DEAA fluorene (RMI 11,002da), and Corynebacterium parvum and some observations on the role of host resistance and herpes-like lesions in tumor growth.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D004048:Diethylamines / Q000627:therapeutic use; D005449:Fluorenes / Q000627:therapeutic use*; D006566:Herpesviridae Infections / Q000473:pathology; D006801:Humans; D007109:Immunity; D007772:Lactate dehydrogenase-elevating virus / Q000276:immunology; D008213:Lymphocyte Activation; D008380:Marek Disease / Q000473:pathology; D009175:Mycoplasma Infections / Q000473:pathology; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011200:Poultry; D011425:Propionibacterium acnes / Q000276:immunology*; D018139:Simplexvirus / Q000276:immunology; D013994:Tilorone / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D004048:Diethylamines; D005449:Fluorenes; C006244:RMI 11002; D013994:Tilorone